231 related articles for article (PubMed ID: 23971873)
1. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
Blomain ES; Lin JE; Kraft CL; Trela UT; Rock JM; Aing AS; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):557-64. PubMed ID: 23971873
[TBL] [Abstract][Full Text] [Related]
2. GUCY2C ligand replacement to prevent colorectal cancer.
Blomain ES; Pattison AM; Waldman SA
Cancer Biol Ther; 2016 Jul; 17(7):713-8. PubMed ID: 27104761
[TBL] [Abstract][Full Text] [Related]
3. Guanylyl cyclase C signaling axis and colon cancer prevention.
Pattison AM; Merlino DJ; Blomain ES; Waldman SA
World J Gastroenterol; 2016 Sep; 22(36):8070-7. PubMed ID: 27688649
[TBL] [Abstract][Full Text] [Related]
4. Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer.
Aka AA; Rappaport JA; Pattison AM; Sato T; Snook AE; Waldman SA
Expert Rev Clin Pharmacol; 2017 May; 10(5):549-557. PubMed ID: 28162021
[TBL] [Abstract][Full Text] [Related]
5. Linaclotide: first global approval.
McWilliams V; Whiteside G; McKeage K
Drugs; 2012 Nov; 72(16):2167-75. PubMed ID: 23083112
[TBL] [Abstract][Full Text] [Related]
6. Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
Góngora-Benítez M; Tulla-Puche J; Albericio F
Future Med Chem; 2013 Mar; 5(3):291-300. PubMed ID: 23464519
[TBL] [Abstract][Full Text] [Related]
7. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
Weinberg DS; Lin JE; Foster NR; Della'Zanna G; Umar A; Seisler D; Kraft WK; Kastenberg DM; Katz LC; Limburg PJ; Waldman SA
Cancer Prev Res (Phila); 2017 Jun; 10(6):345-354. PubMed ID: 28396341
[TBL] [Abstract][Full Text] [Related]
8. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer.
Rappaport JA; Waldman SA
Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1125-1137. PubMed ID: 32945718
[No Abstract] [Full Text] [Related]
9. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
10. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention.
Yarla NS; Gali H; Pathuri G; Smriti S; Farooqui M; Panneerselvam J; Kumar G; Madka V; Rao CV
Semin Cancer Biol; 2019 Jun; 56():168-174. PubMed ID: 30189250
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology and clinical potential of guanylyl cyclase C agonists in the treatment of ulcerative colitis.
Pitari GM
Drug Des Devel Ther; 2013; 7():351-60. PubMed ID: 23637522
[TBL] [Abstract][Full Text] [Related]
12. Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics.
Lin JE; Valentino M; Marszalowicz G; Magee MS; Li P; Snook AE; Stoecker BA; Chang C; Waldman SA
Toxins (Basel); 2010 Aug; 2(8):2028-54. PubMed ID: 22069671
[TBL] [Abstract][Full Text] [Related]
13. Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers.
Weinberg DS; Foster NR; Della'Zanna G; McMurray RP; Kraft WK; Pallotto A; Kastenberg DM; Katz LC; Henry CH; Moleski SM; Limburg PJ; Waldman SA
Cancer Biol Ther; 2021 Dec; 22(10-12):544-553. PubMed ID: 34632925
[TBL] [Abstract][Full Text] [Related]
14. GUCY2C: at the intersection of obesity and cancer.
Kim GW; Lin JE; Waldman SA
Trends Endocrinol Metab; 2013 Apr; 24(4):165-73. PubMed ID: 23375388
[TBL] [Abstract][Full Text] [Related]
15. Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUCY2C Paracrine Signaling Axis.
Lin JE; Colon-Gonzalez F; Blomain E; Kim GW; Aing A; Stoecker B; Rock J; Snook AE; Zhan T; Hyslop TM; Tomczak M; Blumberg RS; Waldman SA
Cancer Res; 2016 Jan; 76(2):339-46. PubMed ID: 26773096
[TBL] [Abstract][Full Text] [Related]
16. Can colorectal cancer be prevented or treated by oral hormone replacement therapy?
Li P; Lin JE; Schulz S; Pitari GM; Waldman SA
Curr Mol Pharmacol; 2009 Nov; 2(3):285-92. PubMed ID: 20021465
[TBL] [Abstract][Full Text] [Related]
17. GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?
Li P; Lin JE; Marszlowicz GP; Valentino MA; Chang C; Schulz S; Pitari GM; Waldman SA
Drug News Perspect; 2009; 22(6):313-8. PubMed ID: 19771320
[TBL] [Abstract][Full Text] [Related]
18. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy.
Li P; Lin JE; Snook AE; Gibbons AV; Zuzga DS; Schulz S; Pitari GM; Waldman SA
Clin Transl Sci; 2008 Sep; 1(2):163-7. PubMed ID: 19727435
[TBL] [Abstract][Full Text] [Related]
20. Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.
Lin JE; Li P; Pitari GM; Schulz S; Waldman SA
Future Oncol; 2009 May; 5(4):509-22. PubMed ID: 19450179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
